2025 catalysts: New modality showdowns 

The same genetic disease indications are popping up in platform company pipelines again and again, and it’s time to see which modalities work best in the applications, and which can succeed on the market. With readouts and launches on the way for multiple modalities in the same diseases, the 2025 new modality catalysts are teeing up a technology showdown years in the making. 

Base editing and RNA editing will face off in alpha-1-antitrypsin deficiency (AATD). A small molecule, gene editor, siRNA and antisense therapy are all vying for the transthyretin amyloidosis with cardiomyopathy (ATTR-CM). And multiple modalities are testing the cardiovascular disease waters through genetic subsets within prevalent indications. ...